The Company develops and markets computer and mobile software for patient communication, care coordination.
Today, DocsInk maintains a steady increase in its user base by navigating the healthcare industry’s everchanging demands and constantly evolving to meet the needs of our providers and their patient lives. DocsInk LLC produces health care software. DocsInk addresses the administrative, billing, secure commun ication, data-sharing and clinical work-flow needs associated with collaborative-care models. One-Tap Telehealth One-tap with no patient app downloads. Beyond our technology, that is native to Mac, PC, iOS, and Android, our team is dedicated to providing you with the customer support and user experience that is second to none.ĭocsInk’s growth over the years is graciously attributed to the generous referrals of our current user-base to other healthcare organizations around the country. Remote Patient Monitoring Remote Patient Monitoring allows you to monitor your patients & bill for your time. Then by utilizing the SMART on FHIR platform and protocols, DocsInk has set its platform to create truly integrated and system agnostic services with all EHR/PM systems.
Download our General Guidelines to the Final 2021 CMS RPM Guidelines below. We provide simple, effective solutions that will improve the speed, efficiency, accuracy, and options in the delivery of patient care. On December 1, 2020, the Center for Medicare and Medicaid Services (CMS) issued a final ruling that includes updates on policy changes for Remote Patient Monitoring. Delivered as a Software-as-a-Service (“SaaS”) secure communication company, DocsInk is improving the way technology integrates with the various workflows of the healthcare industry. DocsInk® differentiates its software from the competition by simultaneously addressing the fiscal, communication, and connectivity needs of medical professionals. And DocsInk, LLC does its best every day to help providers overcome the revenue challenges associated with the shift towards value-based care.
0 kommentar(er)
